Trustiva
Tenofovir Disoproxil · Efavirenz · Emtricitabine
Tenofovir disoproxil and efavirenz tablets for HIV-1. They combine two antiretrovirals to keep the virus in check.
- Categories
- HIV Management · Antivirals
- Active ingredients
- Tenofovir Disoproxil · Efavirenz · Emtricitabine
- Route
- Oral use
- Form
- Tablet
- Strengths
- 300mg + 600mg + 200mg
Prescription and consultation requirements for Trustiva vary by destination and are determined by the fulfilment partner.
Trustiva details
- Alternative names
- tenofovir, efavirenz, emtricitabine
- Therapeutic class
- Nucleoside Analog and Non-Nucleoside Reverse Transcriptase Inhibitor Combination
- Pharmacological class
- Antiretroviral Combination
- Minor side effects
- dizziness; headache; insomnia
- Moderate side effects
- vivid dreams; rash; diarrhoea
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Hetero Healthcare
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Rifampin; Simvastatin; St. John's Wort
- Age restrictions
- Approved for adults weighing over thirty-five kilograms.
Contraindications
severe renal impairment; concurrent highly CYP3A4-dependent therapies; hepatic failure
Serious side effects
lactic acidosis, requires immediate medical attention; severe bone marrow suppression, requires immediate medical attention; suicidal ideation, requires immediate medical attention
Patient summary
Tenofovir disoproxil and efavirenz tablets for HIV-1. They combine two antiretrovirals to keep the virus in check.
Mechanism of action
Efavirenz blocks reverse transcriptase non-competitively, while tenofovir and emtricitabine act as DNA chain terminators.
Pregnancy and breastfeeding
Pregnancy: Avoid in first trimester. Discontinue breastfeeding to prevent transmission. Breastfeeding: Confirm breastfeeding suitability with a qualified clinician or pharmacist before use.